Gene clues could personalize Crohn's treatment
NCT ID NCT07263477
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study looked at whether differences in the IL-7 receptor gene are linked to the risk of developing Crohn's disease and how well patients respond to the drug infliximab. Researchers analyzed genetic samples from 303 Crohn's patients and 514 healthy people. The goal is to better understand who might benefit most from this treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
infliximab
What this could lead to
If successful, this could help identify which Crohn's patients are more likely to benefit from infliximab, enabling more personalized treatment.
What could go wrong
This is a retrospective, observational study, not a controlled trial. The findings are preliminary and need confirmation in larger, prospective studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CROHN DISEASE (CD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
the Second Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, 325000, China